Ruboxistaurin (Standard)

Ruboxistaurin (Standard) is the analytical standard of Ruboxistaurin. This product is intended for research and analytical applications. Ruboxistaurin (LY333531) is an orally active, selective PKC beta inhibitor (Ki=2 nM) . Ruboxistaurin exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin inhibits PKC beta II with an IC50 of 5.9 nM[1][2].

Product Specifications

CAS Number

[169939-94-0]

Product Name Alternative

LY333531 (Standard)

UNSPSC

12352005

Target

PKC; Reference Standards

Related Pathways

Epigenetics; Others; TGF-beta/Smad

Field of Research

Metabolic Disease

Smiles

O=C1NC(C(C2=CN(C3=CC=CC=C32)CCO[C@H](CN(C)C)CC4)=C1C5=CN4C6=CC=CC=C56)=O

Molecular Formula

C28H28N4O3

Molecular Weight

468.55

References & Citations

[1]Jirousek MR, et al. (S) -13-[ (dimethylamino) methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e, k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3 (2H) -d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996;39 (14) :2664-2671.|[2]Ruboxistaurin: LY 333531. Drugs R D. 2007;8 (3) :193-199.|[3]Kunt T, et al. The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro. J Diabetes Sci Technol. 2007 Nov;1 (6) :929-35.|[4]Nonaka A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000 Aug;41 (9) :2702-6.